Levy AP - Search Results

1

Antioxidant vitamins and their use in preventing cardiovascular disease.

Farbstein D, Kozak-Blickstein A, Levy AP. Farbstein D, et al. Among authors: levy ap. Molecules. 2010 Nov 9;15(11):8098-110. doi: 10.3390/molecules15118098. Molecules. 2010. PMID: 21063272 Free PMC article. Review.

2

The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women.

Levy AP, Friedenberg P, Lotan R, Ouyang P, Tripputi M, Higginson L, Cobb FR, Tardif JC, Bittner V, Howard BV. Levy AP, et al. Diabetes Care. 2004 Apr;27(4):925-30. doi: 10.2337/diacare.27.4.925. Diabetes Care. 2004. PMID: 15047650 Clinical Trial.

3

Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.

Levy AP. Levy AP. Isr Med Assoc J. 2004 May;6(5):308-10. Isr Med Assoc J. 2004. PMID: 15151377 Free article. Review. No abstract available.

4

Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy.

Levy AP. Levy AP. Pharmacol Ther. 2006 Nov;112(2):501-12. doi: 10.1016/j.pharmthera.2006.05.002. Epub 2006 Jul 18. Pharmacol Ther. 2006. PMID: 16854468 Review.

5

In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease.

Asleh R, Levy AP. Asleh R, et al. Among authors: levy ap. Vasc Health Risk Manag. 2005;1(1):19-28. doi: 10.2147/vhrm.1.1.19.58930. Vasc Health Risk Manag. 2005. PMID: 17319095 Free PMC article. Review.

6

Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial.

Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Milman U, et al. Among authors: levy ap, levy y. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. doi: 10.1161/ATVBAHA.107.153965. Epub 2007 Nov 21. Arterioscler Thromb Vasc Biol. 2008. PMID: 18032779 Clinical Trial.

7

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.

Levy AP, Blum S. Levy AP, et al. Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1105-11. doi: 10.1586/14779072.5.6.1105. Expert Rev Cardiovasc Ther. 2007. PMID: 18035926 Review.

8

Haptoglobin: basic and clinical aspects.

Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R, Farbstein D, Pollak M, Soloveichik YZ, Strauss M, Alshiek J, Livshits A, Schwartz A, Awad H, Jad K, Goldenstein H. Levy AP, et al. Among authors: levy ns. Antioxid Redox Signal. 2010 Feb;12(2):293-304. doi: 10.1089/ars.2009.2793. Antioxid Redox Signal. 2010. PMID: 19659435 Review.

9

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.

Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, Levy NS, Miller-Lotan R, Asleh R, Levy AP. Blum S, et al. Among authors: levy ap, levy ns. Pharmacogenomics. 2010 May;11(5):675-84. doi: 10.2217/pgs.10.17. Pharmacogenomics. 2010. PMID: 20415560 Free PMC article.

10

The genetics of vascular complications in diabetes mellitus.

Farbstein D, Levy AP. Farbstein D, et al. Among authors: levy ap. Cardiol Clin. 2010 Aug;28(3):477-96. doi: 10.1016/j.ccl.2010.04.005. Cardiol Clin. 2010. PMID: 20621252 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page